183 related articles for article (PubMed ID: 25229296)
1. Effectiveness of miltefosine-pentoxifylline compared to miltefosine in the treatment of cutaneous leishmaniasis in C57Bl/6 mice.
Santarem AA; Greggianin GF; Debastiani RG; Ribeiro JB; Polli DA; Sampaio RN
Rev Soc Bras Med Trop; 2014 Jul; 47(4):517-20. PubMed ID: 25229296
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of the efficacy of systemic miltefosine associated with photodynamic therapy with liposomal chloroaluminium phthalocyanine in the treatment of cutaneous leishmaniasis caused by Leishmania (L.) amazonensis in C57BL/6 mice.
Ribeiro JBP; Miranda-Vilela AL; Graziani D; Gomes MRA; Amorim AAS; Garcia RD; de Souza Filho J; Tedesco AC; Primo FL; Moreira JR; Lima AV; Sampaio RNR
Photodiagnosis Photodyn Ther; 2016 Mar; 13():282-290. PubMed ID: 26306406
[TBL] [Abstract][Full Text] [Related]
3. Efficacy of tamoxifen and miltefosine combined therapy for cutaneous leishmaniasis in the murine model of infection with Leishmania amazonensis.
Trinconi CT; Reimão JQ; Coelho AC; Uliana SR
J Antimicrob Chemother; 2016 May; 71(5):1314-22. PubMed ID: 26851606
[TBL] [Abstract][Full Text] [Related]
4. [Comparative study between oral miltefosine and parenteral N-metil glucamine antimoniate for the treatment of experimental leishmaniasis caused Leishmania (Leishmania) amazonensis].
Costa Filho AV; Lucas IC; Sampaio RN
Rev Soc Bras Med Trop; 2008; 41(4):424-7. PubMed ID: 18853022
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of miltefosine treatment in Leishmania amazonensis-infected BALB/c mice.
Godinho JL; Simas-Rodrigues C; Silva R; Ürmenyi TP; de Souza W; Rodrigues JC
Int J Antimicrob Agents; 2012 Apr; 39(4):326-31. PubMed ID: 22226653
[TBL] [Abstract][Full Text] [Related]
6. Combined suboptimal schedules of topical paromomycin, meglumine antimoniate and miltefosine to treat experimental infection caused by Leishmania (Viannia) braziliensis.
de Morais-Teixeira E; Aguiar MG; Soares de Souza Lima B; Ferreira LA; Rabello A
J Antimicrob Chemother; 2015 Dec; 70(12):3283-90. PubMed ID: 26346991
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of miltefosine monotherapy and pentoxifylline associated with pentavalent antimony in treating mucosal leishmaniasis.
Ventin F; Cincurá C; Machado PRL
Expert Rev Anti Infect Ther; 2018 Mar; 16(3):219-225. PubMed ID: 29411659
[TBL] [Abstract][Full Text] [Related]
8. Oral miltefosine to treat new world cutaneous leishmaniasis.
Soto J; Toledo JT
Lancet Infect Dis; 2007 Jan; 7(1):7. PubMed ID: 17182338
[No Abstract] [Full Text] [Related]
9. Efficacy of miltefosine for Bolivian cutaneous leishmaniasis.
Soto J; Rea J; Balderrama M; Toledo J; Soto P; Valda L; Berman JD
Am J Trop Med Hyg; 2008 Feb; 78(2):210-1. PubMed ID: 18256415
[TBL] [Abstract][Full Text] [Related]
10. Combination oral therapy against Leishmania amazonensis infection in BALB/c mice using nanoassemblies made from amphiphilic antimony(V) complex incorporating miltefosine.
Carregal VM; Lanza JS; Souza DM; Islam A; Demicheli C; Fujiwara RT; Rivas L; Frézard F
Parasitol Res; 2019 Oct; 118(10):3077-3084. PubMed ID: 31401656
[TBL] [Abstract][Full Text] [Related]
11. In vivo activity of perifosine against Leishmania amazonensis.
Cabrera-Serra MG; Valladares B; Piñero JE
Acta Trop; 2008 Oct; 108(1):20-5. PubMed ID: 18801328
[TBL] [Abstract][Full Text] [Related]
12. Combined topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) major leads to reduction in both lesion size and systemic parasite burdens.
Aguiar MG; Silva DL; Nunan FA; Nunan EA; Fernandes AP; Ferreira LA
J Antimicrob Chemother; 2009 Dec; 64(6):1234-40. PubMed ID: 19825819
[TBL] [Abstract][Full Text] [Related]
13. In vitro and in vivo miltefosine susceptibility of a Leishmania amazonensis isolate from a patient with diffuse cutaneous leishmaniasis.
Coelho AC; Trinconi CT; Costa CH; Uliana SR
PLoS Negl Trop Dis; 2014 Jul; 8(7):e2999. PubMed ID: 25033218
[TBL] [Abstract][Full Text] [Related]
14. Treatment of New World cutaneous leishmaniasis with miltefosine.
Soto J; Berman J
Trans R Soc Trop Med Hyg; 2006 Dec; 100 Suppl 1():S34-40. PubMed ID: 16930649
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of the Ability of Miltefosine Associated with Topical GM-CSF in Modulating the Immune Response of Patients with Cutaneous Leishmaniasis.
Peixoto F; Nascimento MT; Costa R; Silva J; Renard G; Guimarães LH; Penna G; Barral-Netto M; Carvalho LP; Machado PRL; Carvalho EM
J Immunol Res; 2020; 2020():2789859. PubMed ID: 32851099
[TBL] [Abstract][Full Text] [Related]
16. Miltefosine Combined with Intralesional Pentamidine for
Soto J; Soto P; Ajata A; Rivero D; Luque C; Tintaya C; Berman J
Am J Trop Med Hyg; 2018 Nov; 99(5):1153-1155. PubMed ID: 30255833
[TBL] [Abstract][Full Text] [Related]
17. Reductions in skin and systemic parasite burdens as a combined effect of topical paromomycin and oral miltefosine treatment of mice experimentally infected with Leishmania (Leishmania) amazonensis.
Aguiar MG; Pereira AM; Fernandes AP; Ferreira LA
Antimicrob Agents Chemother; 2010 Nov; 54(11):4699-704. PubMed ID: 20713665
[TBL] [Abstract][Full Text] [Related]
18. Anti-leishmanial activity of a topical miltefosine gel in experimental models of New World cutaneous leishmaniasis.
Neira LF; Mantilla JC; Escobar P
J Antimicrob Chemother; 2019 Jun; 74(6):1634-1641. PubMed ID: 30815688
[TBL] [Abstract][Full Text] [Related]
19. Chronic cutaneous leishmaniasis in an immunocompetent patient: response to miltefosine.
Ruiz-Villaverde R; Sánchez-Cano D; Villaverde-Gutierrez C
J Eur Acad Dermatol Venereol; 2007 May; 21(5):695-6. PubMed ID: 17447994
[No Abstract] [Full Text] [Related]
20. Cost-effectiveness of meglumine antimoniate versus miltefosine caregiver DOT for the treatment of pediatric cutaneous leishmaniasis.
Berger BA; Cossio A; Saravia NG; Castro MDM; Prada S; Bartlett AH; Pho MT
PLoS Negl Trop Dis; 2017 Apr; 11(4):e0005459. PubMed ID: 28384261
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]